Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
2001
Effects of NU1025 on Cancer Cell Treatment
publication
Author Information
Author(s): Bowman K J, Newell D R, Calvert A H, Curtin N J
Primary Institution: Cancer Research Unit, University of Newcastle upon Tyne Medical School
Hypothesis
Does the PARP inhibitor NU1025 enhance the effectiveness of topoisomerase inhibitors in cancer cells?
Conclusion
NU1025 increases the effectiveness of the topoisomerase I inhibitor camptothecin but does not affect the topoisomerase II inhibitor etoposide.
Supporting Evidence
- NU1025 increased the cytotoxicity of camptothecin by 2.6-fold.
- NU1025 increased camptothecin-induced DNA strand breaks by 2.5-fold.
- NU1025 did not enhance the effects of etoposide on DNA strand breakage.
Takeaway
A new drug called NU1025 helps another cancer drug work better by making it harder for cancer cells to fix their damaged DNA.
Methodology
The study investigated the effects of NU1025 on the cytotoxicity of topoisomerase I and II inhibitors in L1210 cells.
Participant Demographics
L1210 cells, a type of cancer cell line.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website